Category: Uncategorized

KAPIHAN AT TALAKAYAN SA FDA FOR MANUFACTURERS AND DISTRIBUTORS OF FOOD CONTRACT ARTICLES

The Toxicology Section of the Common Services Laboratory (CSL) shall be holding the aforementioned activity on 04 December 2019 (Wednesday) 9:30 AM — 12:00 PM at the Food and Drug Action Center (FDAC) Meeting Room, located at 3rd Level of Starmall, Alabang, Muntinlupa City.

The Kapihan at Talakayan aims to provide a venue for discussion, clarification, and/or suggestion on the implementation of FDA Citizen’s Charter on Application for Food Suitability Evaluation of Food Contact Articles (Voluntary).

All interested parties may signify their attendance thru registration by e-mail at [email protected], [email protected], and [email protected] Registration shall be on a first come, first served basis and one (1) representative shall be allowed per company.

A total of fifteen (15) slots shall be made available and confirmation as attendee shall also be made via e-mail.

For your information and guidance.

Attachment:-> KAPIHAN AT TALAKAYAN SA FDA FOR MANUFACTURERS AND DISTRIBUTORS OF FOOD CONTRACT ARTICLES

FDA SYSTEM MAINTENANCE

Please be informed that the IT System of the Information and Communication Technology Management Division of the Policy and Planning Services (PPS-ICTMD) will be undergoing check and maintenance in order to migrate from a local server to Cloud on October 31 at (6PM) to November 4, 2019 at (5AM).

We regret to inform you that all ICTM system will be temporarily unavailable.

We sincerely apologize.

Thank you for your cooperation and understanding.

Attachment:-> FDA SYSTEM MAINTENANCE from October 31 to November 4 2019

Cancellation of “Regional Cascading of Administrative Orders on the Regulation of Household/Urban Hazardous Substances (HUHS), Household/Urban Pesticides (HUPs), and Pest Control Operators (PCOs) and Pesticide Handlers, and Implementing Rules and Regulations (IRR) of RA 10620

This is to inform all concerned stakeholders that the “Regional Cascading of Administrative Orders on the Regulation of Household/Urban Hazardous Substances (HUHS), Household/Urban Pesticides (HUPs), and Pest Control Operators (PCOs) and Pesticide Handlers, and Implementing Rules and Regulations (IRR) of RA 10620” in Davao City will not push through on 24-25 October 2019 due to low number of registered participants.

The new schedule and confirmed venue will be announced accordingly.

For your information and guidance.

Thank you.

Attachment:-> Cancellation of Regional Cascading of Administrative Orders on the Regulation of (HUHS) ,(HUPs), and (PCOs) Pesticide Handlers, and Implementing Rules and Regulations (IRR) of RA 10620 in Davao City

/ In Uncategorized / By Administrator / Comments Off on Cancellation of “Regional Cascading of Administrative Orders on the Regulation of Household/Urban Hazardous Substances (HUHS), Household/Urban Pesticides (HUPs), and Pest Control Operators (PCOs) and Pesticide Handlers, and Implementing Rules and Regulations (IRR) of RA 10620

MANUFACTURER OF UNREGISTERED GLUTATHIONE PRODUCT FOUND GUILTY BY THE REGIONAL TRIAL COURT

Press Release 15 October 2019

On 04 September 2019, the Regional Trial Court in Mandaluyong City promulgated a Judgment against Leo Plantilla Ortiz (Ortiz), owner of JLO General Merchandise, finding him guilty of violation of Republic Act No. 9711. He was sentenced to pay the fine of One Hundred Thousand Pesos (Php100,000.00).

The accused Ortiz was found to have willfully, unlawfully and feloniously, manufactured or caused the manufacture of different health products identified as: (a) 12-in-1 Gluta Lipo with Glutathione and L- Carnitine Lemon Flavor (also referred to as Gluta Lipo 12-in-1 (Glutathione) Whitening and Slimming Juice, 12- Gluta Lipo Whitening Juice(Glutathione); (b) 12-in1 Gluta Lipo Detox Coffee (also referred to as 12-in-1 Gluta Lipo Detox Coffee (Glutathione); and (c) Gluta Lipo Ultima Plus capsules without first registering said products before the Food and Drug Administration (FDA). The agents of the Regulatory Enforcement Unit of the FDA made the arrest and filed criminal charges against the accused.

He was charged of clearly violating Section 10 (a) and (j) Republic Act No. 9711 known as the Food and Drug Administration Act (FDA) of 2009, amending Section 11 of Republic Act No. 3720, as amended, which provide:

“SEC. 10. Section 11, subsections (a), (b), (d), (g), (j), (k) and (l) of Republic Act No. 3720, as amended, are hereby further amended to read as follows:

“SEC. 11. The following acts and the causing thereof are hereby prohibited:

“(a) The manufacture, importation, exportation, sale, offering for sale, distribution, transfer, non-consumer use, promotion, advertising, or sponsorship of any health product that is adulterated, unregistered or misbranded.

“6) The manufacture, importation, exportation, sale, offering for sale, distribution,

transfer, non-consumer use, promotion, advertisement, or sponsorship of any health

product which, although requiring registration, is not registered with the FDA

pursuant to this Act.”

In a statement, Undersecretary for Health and FDA’s Director General, Rolando Enrique D. Domingo, declared that this verdict of the Court shall serve as a warning to all concerned people or entities to strictly comply with the provisions of Republic Act No. 3720, as amended, and further amended by Republic Act No. 9711, as well as, other FDA-implemented laws and secure the required appropriate licenses to operate an establishment and register their products.

“To those who continue with their illegal and nefarious activities of manufacturing, importation, exportation, sale, offering for sale, distribution, transfer, non-consumer use, promotion, advertising, or sponsorship of any health product without the benefit of registration and license to operate, at the expense of the health of the people, the FDA shall be relentless in pursuing legal actions against them,” he said.

Cascading of Administrative Orders on the Regulation of Household/Urban Hazardous Substances (HUHS), Household/Urban Pesticides (HUPs), and Pest Control Operators (PCOs) and Pesticide Handlers, and Implementing Rules and Regulations (IRR) of RA 10620

DATE: 21, 22, 24, 25, 28, 29 & 30 October 2019
VENUE: Venue to be Determined within Cagayan de Oro, Davao City, Ilo-ilo City, and Pampanga

In the interest of the service, the Center for Cosmetics Regulation and Research (CCRR), Food and Drug Administration (FDA), shall conduct a “Regional Cascading of the Administrative Orders on the Regulation of Household/Urban Hazardous Substances (HUHS), Household/Urban Pesticides (HUPs), and Pest Control Operators (PCOs) and Pesticide Handlers, and Implementing Rules and Regulations of RA 10620” on the following dates:

  DAY 1:

21 October 2019: Cagayan de Oro

24 October 2019: Davao City

28 October 2019: Ilo-ilo City

29 October 2019: Pampanga

DAY 2:

22 October 2019: Cagayan de Oro

25 October 2019: Davao City

29 October 2019: Ilo-ilo City

30 October 2019: Pampanga

AM Session
8:30-9:00 AM Registration
9:00-10:00 AM Presentation of IRR of RA10620: Toy and Game Safety Labeling Act of 2013 Presentation of AO 2019-0008:

AO on the Registration of HUPs

10:00-12:00 NN Open Forum
PM Session
1:30-2:00 PM Registration
2:00-3:00 PM Presentation of AO 2019-0019:

AO on HUHS

Presentation of AO 2019-0010:

AO on PCOs

3:00-5:00 PM Open Forum

All concerned stakeholders are invited to attend. Registration through this LINK  is on a first-come, first-serve basis as only the first one-hundred (100) pre-registrants (per session) shall be accommodated. To maximize the number of attendees, please limit your representative to only one (1) per company/industry association.

For any concerns or inquiries, kindly contact CCRR at (02) 857-1900 local 8107 or 8113, or through email at [email protected] .

Attachment:-> Announcement – Regional Cascading of 4AOs

/ In Uncategorized / By Administrator / Comments Off on Cascading of Administrative Orders on the Regulation of Household/Urban Hazardous Substances (HUHS), Household/Urban Pesticides (HUPs), and Pest Control Operators (PCOs) and Pesticide Handlers, and Implementing Rules and Regulations (IRR) of RA 10620

Notice of Transfer of Venue for ITB No. 2019-017-PPS

To: ALL INTERESTED/ACCRECITED SUPPLIERS:

This pertains to the Opening of Bids on 04 October 2019 (Friday) at 1:30 PM for the above stated project. Kindly be advised that the City Health Office of Muntinlupa City had announced that they will be conducting fumigation at the FDA premises on the same date at 12:01 after the “Orientation on Awareness of Dengue” thus employees were advised to vacate the premises.

In this regard, the venue for the Bid Opening of the above stated project will be transferred from FDA-BAC Secretariat Room , Annex Bldg, Food and Drug Administration, Civic Drive, Filinvest Corporate City, Alabang City to the FDAC Office, 3rd Floor Starmall, Alabang, Muntinlupa City.

For information and please be guided accordingly.

Attachment:> Bid Supplement Notice of Transfer of Venue

PRESS RELEASE 22 August 2019: Warning retailers on promoting and selling of alcoholic beverages to minors (below 18 years old)

The Department of Health – Food and Drug Administration released recently an advisory warning retailers on promoting and selling of alcoholic beverages to minors (below 18 years old). This is in light of recent reports that alcopops, sweet and often fruit-flavored or fizzy alcoholic beverages, are being sold by retailers, such as supermarkets, groceries and convenience stores to minors, alongside with juice drinks and other non-alcoholic beverages.

To ensure health and welfare of minors and to remind retailers on the ethical sale of alcoholic beverages, the DOH-FDA is sternly reminding all retailers to refrain from the promotion and selling of all alcoholic beverages, especially alcopops, to minors. Further, retailers are reminded to include appropriate prominent signage for liquors/alcoholic drinks in their respective stores and ensure the conduct of appropriate verification of age of customers.

The general public is enjoined to be vigilant from food retailers who continuously sell alcoholic beverages to minors. Please report these erring food retailers to eReport, the online reporting facility of the Food and Drug Administration, which can be accessed at www.fda.gov.ph/ereport or call 857-1900 local 8112 and 8115.

Attachment-> : Press Release 22 August 2019

RESCHEDULING OF QCCRR–MIN AND ULS-RX IN OBSERVANCE OF THE LOCAL HOLIDAY IN REGION X ON 28 AUGUST 2019

A N N O U N C E M E N T

Please be informed of the following changes of the FDA Academy QPIRA Seminar for Center for  Cosmetics  Regulation  and  Research  for  Mindanao  Stakeholders  (QCCRR-MIN)  and Unified  Licensing  Seminar   for  Region  X  (ULS-RX) in observance of the local holiday in Cagayan de Oro City on 28 August 2019:

ACTIVITY TITLE FROM

(ORIGINAL SCHEDULE)

TO

(NEW SCHEDULE)

Center for Cosmetics Regulation and Research QPIRA Seminar  for Mindanao (Cagayan de Oro) 28-29 August 2019 29-30 August 2019
Unified Licensing Seminar for Region X (Iligan City) 28 August 2019 29 August 2019
Unified Licensing Seminar for Region X (Cagayan de Oro City) 29 August 2019 30 August 2019

Our sincere apologies for any inconvenience this change in seminar schedule have cause.

For inquiries and other concerns, please call the FDA Academy at telephone number (02) 877-0259 or email at [email protected].

Please be guided accordingly.

Attachment-> : RESCHEDULING OF QCCRR–MIN AND ULS-RX

Draft Amendment to Administrative Order No. 2018-0002 dated 26 January 2018, re: Guidelines Governing the Issuance of an Authorization for a Medical Device based on the ASEAN Harmonized Technical Requirements

Announcement on the Submission of Comments for the “Draft Amendment to Administrative Order No. 2018-0002 dated 26 January 2018, re: Guidelines Governing the Issuance of an Authorization for a Medical Device based on the ASEAN Harmonized Technical Requirements”

In the interest of service, notice is hereby given that all concerned parties may submit their comments for the draft “Amendment to Administrative Order No. 2018-0002 dated 26 January 2018, re: Guidelines Governing the Issuance of an Authorization for a Medical Device based on the ASEAN Harmonized Technical Requirements” to [email protected] on or before 31 July 2019.

Thank you.

Draft Amendment to Administrative Order No. 2018-0002 dated 26 January 2018

/ In Uncategorized / By Administrator / Comments Off on Draft Amendment to Administrative Order No. 2018-0002 dated 26 January 2018, re: Guidelines Governing the Issuance of an Authorization for a Medical Device based on the ASEAN Harmonized Technical Requirements

Center for Food Regulation and Research (CFRR) Strategic Plan on 29-31 May 2019

Please be informed that the Center for Food Regulation and Research (CFRR) will conduct its Strategic Planning on 29-31 May 2019 within CALABARZON area.

All transactions will be entertained until 28 May 2019 and will resume on June 2019.

Center for Food Regulation and Researh (CFRR) Strategic Plan on 29-31 May 2019

FROO Operational Planning and Team Building on 28-31 May 2019

Field Regulatory Operations Office (FROO)-South Luzon Cluster will conduct its Operational Planning and Team Building on 28-31 May 2019 within Calabarzon area.

In this regard, skeletal workforce is maintained on the said period. Regular operations will resume on MONDAY, 03 June 2019.

For information and guidance of all concerned stakeholders.

FROO operational Planning and Team Building on 28-31 May 2019

Designation of MERLITO Y. AGUIHAP as Officer-in-Charge of Information Communication and Technology Management Division (ICTMD).

FPO2019-0314-Designation of MERLITO Y. AGUIHAP as Officer-in-Charge of Information Communication and Technology Management Division (ICTMD).

For your information and guidance.

Thank you.

/ In Uncategorized / By Administrator / Comments Off on Designation of MERLITO Y. AGUIHAP as Officer-in-Charge of Information Communication and Technology Management Division (ICTMD).

Designation of DR. OSCAR GUTIERREZ,Chief of Policy Formulation and Program Division as Officer-in Charge of Policy Planning Service (PPS).

FPO2019-0313-Designation of DR. OSCAR GUTIERREZ,Chief of Policy Formulation and Program Division as Officer-in Charge of Policy Planning Service (PPS).

For your information and guidance.

Thank you.

/ In Uncategorized / By Administrator / Comments Off on Designation of DR. OSCAR GUTIERREZ,Chief of Policy Formulation and Program Division as Officer-in Charge of Policy Planning Service (PPS).

Press Release dated May 21, 2019

May 21, 2019

Press Release

The Philippine Nuclear Research Institute- Department of Science and Technology (PNRI-DOST) recently reported that as many as eight out of ten vinegar products are not made from natural sources. According to the report, such products did not undergo the natural process of fermentation of acetic acid, which is the usual process of making vinegar.

Natural vinegar is a product made from the conversion of ethyl alcohol to acetic acid. Synthetic or “fake” vinegar, however, reportedly uses glacial acetic acid, which shortens the production process.

The FDA classifies vinegar as a low risk product, which means that these products are unlikely to contain pathogenic microorganisms and will not normally support their growth because of food characteristics. There is also no evidence that synthetic acetic acid is harmful to health.

While considered low risk, FDA standards consider vinegar a natural product that should have undergone the natural process of alcoholic or acetous fermentation of natural raw materials. If the product contains artificial matter, such as synthetic acetic acid or cloudifying agent, it is considered adulterated.

“The FDA is coordinating with the PNRI for the submission of the results of the analysis, while continuously subjecting vinegar products for testing. Synthetic acetic acid may not be harmful per se, but products using such chemicals shall have their registration with the FDA revoked for misdeclaration,” OIC-FDA Director General Rolando Enrique Domingo said.

VENUE FOR UNIFIED LICENSING SEMINAR (ULS –RVIII) ON 21 MAY 2019

Please be informed that the venue of the Unified Licensing Seminar (ULS – RVIII) on 21 May 2019 will be in TACLOBAN XYZ CORPORATION HOTEL XYZ, P. ZAMORA ST. TACLOBAN CITY

All registrants who received Course Assessment Slips but have not yet received their Course Confirmation Slips are advised to bring with them the following documents:

  • Course Assessment Slip
  • Proof of Payment

For inquiries and other concerns, please call the FDA Academy at telephone number (02) 877 0259.

VENUE FOR UNIFIED LICENSING SEMINAR (ULS –RVIII) ON 21 MAY 2019

VENUE FOR UNIFIED LICENSING SEMINAR (ULS –CAR) ON 21 AND 22 MAY 2019

Please be informed that the venue of the Unified Licensing Seminar (ULS – CAR) on 21 & 22 May 2019 will be in CITYLIGHT HOTEL, 245 Upper General Luna Road, Baguio City

All registrants who received Course Assessment Slips but have not yet received their Course Confirmation Slips are advised to bring with them the following documents:

  • Course Assessment Slip
  • Proof of Payment

For inquiries and other concerns, please call the FDA Academy at telephone number (02) 877 0259.

PH FDA QUALIFIES AS 5th ASEAN INSPECTION SERVICE

PH FDA QUALIFIES AS 5th ASEAN LISTED INSPECTION SERVICE – The Philippine Food and Drug Administration (FDA) has successfully qualified as the 5th ASEAN Listed Inspection Service with the completion of the onsite audit by the Panel of Experts last month. It is now preparing to summit its intent to apply for membership to the prestigious Pharmaceutical Inspection Co-operation Scheme (PIC/S). Shown in the photo are: FDA Director General Nela Charade G. Puno (2nd from Right) in the committee meeting in Geneva, Switzerland to signify FDA’s intent to submit its application for membership. With her are (from left): FDA OIC Deputy Director-General for Field regulatory Operations Office Atty. Emilio L. Polig Jr., current PIC/S Chairman Boon Meow Hoe (Singapore/HSA); and incoming PIC/S chairman Ms. Anne Hayes.

Center for Cosmetic Regulation and Research Strategic Planning on 15-17 May 2019 at a venue within Batangas.

The Center for Cosmetic Regulation and Research will conduct its Strategic Planning on 15-17 May 2019 at a venue within Batangas.
 
In this regard, no transactions will be made on these dates. All operations will resume on MONDAY, 20 May 2019.
 
For Information and guidance of all concerned stakeholders.

FDA eyes Stricter Standards For Vinegar Brands

PRESS RELEASE

MAY 12, 2019

The Food and Drug Administration (FDA) is set to adopt and implement stricter safety and quality standards for vinegar products being sold in the market today, following reports that most of these products are made from synthetic raw materials that may pose health hazards.

FDA Director-General Nela Charade Puno said the agency is now waiting for the final report of the Philippine Nuclear Research Institute (PNRI) which studied samples of some 360 vinegar brands. The PNRI, an arm of the Department of Science and Technology, said that eight out of 10 of these products “contain fake ingredients”, mostly acetic acid.

Puno said the PNRI study will be the basis of new, higher and stricter standards.

The implementation of the new standards will be complimented by an intensive consumer awareness and education program, Puno said.

“However, at this point, let me already tell the peddlers who will continue to sell vinegar products which will not pass the new FDA standards, there will be a major crackdown on these products followed by sustained regulatory enforcement action,” Puno said.

Puno said she anticipates that the new, higher standards and law enforcement action “will be met with resistance from the market vendor sector”. “The FDA recognizes that many buyers prefer cheaper brands,” Puno said.

“However, we cannot allow public health to be exposed to health hazards just to save a few pesos,” Puno explained.

Puno lauded the PNRI for the “valuable research on vinegar products”. She said the PNRI has the capability and the equipment to undertake a research of this magnitude and quality.

“Being experts in nuclear research, the PNRI possesses the needed expertise to come up with this kind of study,” she pointed out. The PNRI uncovered the risk by subjecting the 360 brands to so-called “isotope-based analytical techniques” to determine the contents of each product.

“This is an important contribution on the part of PNRI to public health administration,” Puno said. She explained that “isotope-based analytics” is a component of nuclear research. “The FDA does not have this capability since our research methods and equipment are chemical-based,” she added.

This early, the FDA called on consumers to examine the vinegar products they are purchasing to make sure that these “are made from natural ingredients such as cane sugar and coconut.”

FDA WARNS PUBLIC ON ANTI-HYPERTENSIVE MEDICINE

The Food and Drug Administration (FDA) is reiterating its warning to the public against the administration, sale, and consumption of the anti-hypertension drug product, Losartan Potassium + Hydrochlorothiazide 100mg/25mg Tablet, Director General Nela Charade G. Puno said.

The FDA particularly warns on the drug manufactured by Lek Pharmaceuticals dd, Ljubljana in Slovenia, on a particular batch/lot  which is being voluntarily recalled by Sandoz Inc., per the recent public advisory released by the United States (US) FDA.

The Active Pharmaceutical Ingredient (API), Losartan, manufactured by Zhejiang Huahai Pharmaceuticals Co. Ltd. in Linhai, China, was reported to contain trace amount of the impurity, N-nitrosodiethylamine (NDEA).

The said impurity was classified as a probable human carcinogen as per the World Health Organization (WHO) International Agency for Research on Cancer (IARC). Such is the categorization due to limited evidence of carcinogenicity in humans.

Losartan Potassium + Hydrochlorothiazide is indicated for the treatment of essential hypertension in patients whose blood pressure is not adequately controlled on losartan or hydrochlorothiazide alone.

Although limited to a certain batch/lot (Lot No. JB8912), the FDA is currently monitoring the subject drug product through heightened Post Marketing Surveillance (PMS) operations. It is coordinating with its Market Authorization Holder or MAH for its immediate recall in the Philippines, pending confirmation of their safety for public consumption.

Puno warns retail drug outlets, and other dealers of pharmaceutical products against the sale of this affected lot of Losartan + Hydrochlorothiazide 100mg/25mg Tablet.

FDA initially issued the warning last November 2018 but reitrated the advisory again because of the proliferation of tainted Losartan in the market.

“For everyone’s protection, I am calling on the public to report the sale or distribution of the subject drug product despite the issuance of this Advisory. Kindly email us via [email protected].,” Puno requested.

For more information and inquiries, please e-mail  [email protected] or call the  FDA Action Center hotline (02) 821-1162.

SEMINAR VENUE FOR UNIFIED LICENSING SEMINAR FOR REGION VII (ULS-RVII) IN CEBU ON 7-8 MAY 2019

Please be informed that the Unified Licensing Seminar for Region VII (ULS-RVII) scheduled on 7 & 8 May 2019 in Cebu shall be in CEBU PALM GRASS HOTEL.

  • VENUE          : CEBU PALM GRASS HOTEL
  • ADDRESS     : 68 GEN. JUNQUERA ST. KALUBIHAN CEBU CITY, CEBU

All course registrants who received Course Assessment Slip for the Unified Licensing Seminar are advised to immediately send their proof of payment to confirm your slot for ULS-RVII on 7 & 8 May 2019, otherwise your application will be automatically removed in the e-nroll system.

Rest assured that the stakeholders with the above documents will be accepted to the seminar. For inquiries and other concerns, please call the FDA Academy at telephone number (02) 877 0259.

SEMINAR VENUE FOR UNIFIED LICENSING SEMINAR FOR REGION VII (ULS-RVII) IN CEBU ON 7-8 MAY 2019

FDA backs NGO In war vs. fake cosmetics

Press Statement
26 April 2019

FDA backs NGO
In war vs. fake cosmetics

Food and Drug Administration (FDA) recently expressed support for the call made by a non-government organization (NGO) for an all-out campaign against fake and counterfeit cosmetic products in the local market.

In a statement, FDA Director-General Nela Charade Puno cited the Ecowaste Coalition for “underscoring the need for strong collaboration between government and the civic sector in the war against fake and counterfeit products”.

The NGO recently called on candidates for the Senate and Congress to craft laws that will strengthen the fight against “adulterated and counterfeit cosmetic products”.

The Ecowaste Coalition lauded the gains of the FDA in the campaign against these products. The group added that the FDA has ”made considerable efforts the illegal sale of mercury-contaminated cosmetics such as skin lightening or whitening facial creams”.

The group, however, pointed out that prevailing laws “are not sufficient to stop the sale of these dangerous products”.

Puno said the FDA has continued to step up its law enforcement operations, notching a total of an estimated P114 million worth of unregistered medicines, cosmetics, food and medical products from 2018 to March of this year.

This was accomplished “despite limited resources. ”, she pointed out.

Puno noted that the FDA Regulatory Enforcement Unit (REU) has increased its efforts by 500 percent from 2017 as of the end of last year.

“This has resulted in the seizure of illegal products amounting to hundreds of million as of the end of the first quarter of 2019” Puno said.

A total of 3,183 legal Orders were served last year with about 500 orders already served just in the 1st quarter of 2019 alone.

The FDA has seized a total of almost 9 million verified Counterfeit Products from the said operations conducted from 2018 up to the first quarter of 2019. Puno noted these dangerous Counterfeit items would have gone to unsuspecting consumers were they not confiscated by the FDA.

FDA remains vigilant in its enforcement efforts with 19 Summons with Preventive Measure Orders (SPMO), including Seizure, being implemented just in 2019 alone. It implemented 60 last year.

“The FDA has also padlocked establishments caught selling unregistered products or operating without the required FDA licenses,” Puno disclosed.

She said the seized goods included fake, counterfeit and unregistered wellness and pharmaceutical products in addition to the dangerous cosmetics cited by the EcoWaste Coalition.

Puno said the FDA is set to further intensify the campaign with the use of information technology-based applications.

“With the use of technology, the FDA can track and trace the presence of counterfeits in the medical supply chain,” she explained. She added that the technology has raised the level of public participation in tracking and reporting entities that are selling counterfeits and unregistered products online.

“Because of these measures, more than ever, drug retail businesses importing or selling pharmaceutical products are compelled to comply strictly with the requirements of the FDA for product registration,” Puno pointed out.

“The FDA has also intensified the training of its law enforcement agents in intelligence, surveillance and case build-up skills to ensure that we raise the level of our success in combating the distribution of these dangerous products,” Puno said.

“However, we cannot totally succeed without the support of civic groups like EcoWaste and of our legislators,” Puno added.

-end

SEMINAR VENUE FOR 13 ASEAN MODULES AND GMP MODULES FOR COSMETICS MANUFACTURERS AND TRADERS (GMP-CMT) SEMINAR ON 24-25 APRIL 2019

Please be informed that the 13 ASEAN Modules and GMP Modules for Cosmetics Manufacturers and Traders (GMP-CMT) scheduled on 24-25 April 2019 shall be held at CRIMSON HOTEL.

  • VENUE          : CRIMSON HOTEL
  • ADDRESS     : 2609 Civic Drive Filinvest City Alabang, Muntinlupa City

All course registrants who received Course Assessment Slip for the 13 ASEAN Modules and GMP Modules for Cosmetics Manufacturers and Traders but have not received the Course Confirmation Slip are advised to send their proof of payment and bank validated Training Assessment Slip until Friday, 12 April 2019 to confirm their slot for the training.

Rest assured that the stakeholders with the above documents will be accepted to the seminar. For inquiries and other concerns, please call the FDA Academy at telephone number (02) 877 0259.

SEMINAR VENUE FOR 13 ASEAN MODULES AND GMP MODULES FOR COSMETICS MANUFACTURERS AND TRADERS (GMP-CMT) SEMINAR ON 24-25 APRIL 2019

/ In Uncategorized / By Administrator / Comments Off on SEMINAR VENUE FOR 13 ASEAN MODULES AND GMP MODULES FOR COSMETICS MANUFACTURERS AND TRADERS (GMP-CMT) SEMINAR ON 24-25 APRIL 2019

SUBMISSION OF COURSE REGISTRATION DOCUMENTS FOR WAITLISTED APPLICANTS OF FDA ACADEMY TRAINING SEMINAR

Due to intermittent email error, all waitlisted applicants of FDA Academy Trainings are advised to send their course registration documents to [email protected]. To confirm that your application is a part of the waitlisted applicants, attach the acknowledgement receipt of waitlisted from FDA Academy to your email.

Meantime, please refrain from sending email to [email protected] until further notice. Rest assured that the stakeholders with the correct and complete documents will be assessed to the seminar. For inquiries and other concerns, please call the FDA Academy at telephone number (02) 877 0259.

FOR WAITLISTED APPLICANTS

SEMINAR VENUE FOR CDRRHR QPIRA SEMINAR (QCDRRHR) ON 2-3 APRIL 2019

Please be informed that the Center for Device Regulation, Radiation Health and Research QPIRA Seminar (QCDRRHR) scheduled on 2-3 April 2019 shall be held at ACACIA HOTEL.

VENUE       :     ACACIA HOTEL

ADDRESS  :     5400 EAST ASIA DRIVE CORNER COMMERCE

AVENUE, FILIVEST CORPORATE CITY, ALABANG,  MUNTINLUPA CITY

All course registrants who received Course Assessment Slip for the Unified Licensing Seminar but have not received the Course Confirmation Slip are advised to come in the seminar venue (ACACIA HOTEL) on the scheduled date of seminar with the following documents:

  • Course assessment slip
  • Proof of payment
  • Original Copy of Notarized Affidavit of Undertaking

Rest assured that the stakeholders with the above documents will be accepted to the seminar. For inquiries and other concerns, please call the FDA Academy at telephone number (02) 877 0259.

SEMINAR VENUE FOR CDRRHR QPIRA SEMINAR QCDRRHR ON 2-3 APRIL 2019

SEMINAR VENUE FOR UNIFIED LICENSING SEMINAR FOR REGION I (ULS-I) IN PANGASINAN ON 20 MARCH 2019

Please be informed that the Unified Licensing Seminar for Region I (ULS-I) scheduled on 20 March 2019 in Pangasinan shall be in LENOX HOTEL.

VENUE          : LENOX HOTEL

ADDRESS     : RIZAL STREET DAGUPAN CITY, PANGASINAN

All course registrants who received Course Assessment Slip for the Unified Licensing Seminar but have not received the Course Confirmation Slip are advised to come in the seminar venue (LENOX HOTEL) on the scheduled date of seminar with the following documents:

  • Course assessment slip
  • Proof of payment

Rest assured that the stakeholders with the above documents will be accepted to the seminar. For inquiries and other concerns, please call the FDA Academy at telephone number (02) 877 0259.

SEMINAR VENUE FOR UNIFIED LICENSING SEMINAR FOR REGION I (ULS-I) IN PANGASINAN ON 20 MARCH 2019